Roche posts SKYSCRAPER-01 results for tiragolumab/atezolizumab; registers Phase II Parkinson's trialNov 13Weekly roundup, 9 itemsalectinibastegolimab
AbbVie lifts 2026 EPS guidance, closes Apogee deal, posts Skyrizi and Juvmo approvalsNov 12M&AAbbVieBiovie Inc.Updated
Teva completes Phase 3 asthma inhaler trial; registers vitiligo program and five ANDA actionsNov 6Weekly roundup, 8 itemsalbuterolduvakitug
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Supernus gets orphan exclusivity for ONAPGO, files sNDA for second supplierOct 21Quarterly updateapomorphineSupernus Pharmaceuticals, Inc.Updated
BioVie reports topline Phase 2 SUNRISE-PD results for bezisterim in early Parkinson's diseaseAug 6Clinical readoutbezisterimBiovie Inc.
Supernus sets August 4 date for second-quarter 2026 resultsJul 22Quarterly updateSupernus Pharmaceuticals, Inc.